Platelet Rich Plasma

It is the computer-based cell separator harvesting platelet rich plasma and stem cells from bone marrow. It is a "mini-harvester", which separates blood fractions in an accurate and reproducible manner, so that it is possible to adjust the concentration of individual growth factors for each patient to obtain optimum treatment effect.

It is blood plasma that has been enriched with platelets, a concentrated source of autologous platelets obtained using a unique Angel cell separator. Owing to growth factors they contain, blood platelets have regenerating and rejuvenating properties. They also accelerate healing.

Growth factors are specialist protein contained in blood platelets. Released from blood platelets in a controlled process, growth factors initiate a cascade of repair and regeneration mechanisms, activating other cells and promoting their multiplication at the target site.

It is the computer-based cell separator rather than a centrifuge. Owing to advanced proprietary technology, it ensures achieving platelet concentrate, containing individually tailored growth factors, in a guaranteed and reproducible manner. Angel system additionally enables stem cell harvesting from bone marrow in patients, who do not want liposuction or have not enough adipose tissue to undergo one.

Patient's eligibility for Angel PRP treatment is determined based on medical history and additional tests.
The procedure involves the following steps:
1. Venous blood sample collection.
2. Placing patient's blood in disposable Angel cPRP processing set and running the separation process.
3. The obtained platelet rich plasma is administered by the orthopaedist as an ultrasound-guided injection to the target site.

Sports-related injuries: ligament, tendon or muscle tear.
Chronic orthopaedic conditions such as: tennis elbow, golfer's elbow, runner's knee, Achilles tendon overuse injury or calcaneal spur.
Degenerative joint disease and joint pain
Osseointegration abnormalities (bone nonunion)

This decision is made individually for each patient based on their medical history and orthopaedic assessment.
As a prevention and joint rejuvenation PRP should be used every 1-2 years, depending on your biological age and clinical condition of your joints.

Joint, tendon, ligament and/or muscle regeneration takes time. The effect of growth factor treatment can be assessed at 3 months following the last injection.

Pain sensation depends on your individual sensitivity. The majority of patients do not find it painful.
It involves administration of platelet rich plasma into the joint through the needle by the orthopaedist under local anaesthesia, so you will not feel pain.

PRP treatment is biocompatible with human body.
There is no risk of allergy.
Angel platelet rich plasma harvesting procedure is completely sterile.

Avoid physical activity for four days. Reduce your sports-related activity for two weeks afterwards.
Platelet rich plasma injections may cause transient pain, oedema and/or exudate (fluid accumulation in tissues). The symptoms usually resolve within a few days.

Hematologic (blood) diseases
Cancer
Inflammatory and/or infectious skin diseases
Pregnancy and breastfeeding

It is a treatment method well-studied and assessed in a long term clinical-research. Orthokine is a safe treatment method utilising autologous conditioned serum to treat locomotor system conditions. All substances which inhibit inflammation are therefore obtained from the patient's own blood by using specialist processing technology. The treatment interferes with the cause of inflammation. It inhibits inflammatory processes and protects articular cartilage. Interleukin-1 (IL) is considered the main pro-inflammatory cytokine. This protein intensifies inflammation and - indirectly - makes its symptoms such as pain and swelling more severe. The interleukin-1 receptor antagonist (IL- 1Ra) which is the key mediator of tissue destruction and pain is injected directly into the inflammation site, which enables effective medical intervention alleviating patient symptoms.

.

You will have peripheral blood sample taken using a special EOTII system syringe.
Owing to syringe design, the incubation process causes blood cells to initiate production of different compounds: inflammation inhibiting proteins and substances to promote the growth of various cells. The main anti-inflammatory protein released in the process is interleukin receptor antagonist-1 (IL-1Ra), which blocks interleukin-1 to access its receptor, thus inhibiting development and reducing severity of inflammation.
Patient blood is transferred to a centrifuge, where the separation process yields protein solution (serum), which is injected into the joint.

The obtained serum is divided into 6 equal portions. The first injection into the inflamed area, which the patient receives on day 1., starts stimulating repair and regeneration processes. The remaining plasma is frozen at -20 Celsius degrees.
You will get subsequent injections every 2-3 days.

Arthritis
chronic joint pain
degenerative joint disease
RA (rheumatoid arthritis)
spinal disease
muscle and/or tendon injury

- to reduce your pain threshold
- to prevent increasing pain/ discomfort
- to improve joint mobility and function, and reduce their stiffness
Improving quality of life and patient comfort.

The effect depends on your individual situation and clinical condition. Long-term clinical research demonstrated the analgesic effect to be maintained for over 2 years following Orthokine.

Pain sensation depends on your individual sensitivity. Some patients report feeling pressure in the joint which resolves the next day.

Orthokine has been used in Germany for over 10 years now - and no dangerous health complications have ever been observed.

Hematologic (blood) diseases
Cancer
Pregnancy and breastfeeding
Infection